Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 27, 2012 06:00 ET | Source: Mateon Therapeutics

OXiGENE Receives Notice Related to NASDAQ Minimum Closing Bid Price Rule

SOUTH SAN FRANCISCO, Calif., June 27, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced it has...
June 21, 2012 20:50 ET | Source: Mateon Therapeutics

OXiGENE In-Licenses Rights to Promising Program for Neuroendocrine Tumors

SOUTH SAN FRANCISCO, Calif., June 21, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the...
June 06, 2012 16:10 ET | Source: Mateon Therapeutics

OXiGENE Announces Publication of Key Data Showing Antitumor Activity of ZYBRESTAT(R) Combined With Bevacizumab

SOUTH SAN FRANCISCO, Calif., June 6, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the...
May 09, 2012 16:00 ET | Source: Mateon Therapeutics

OXiGENE Reports First Quarter 2012 Financial Results

SOUTH SAN FRANCISCO, Calif., May 9, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial...
May 02, 2012 16:00 ET | Source: Mateon Therapeutics

OXiGENE Announces First Quarter 2012 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., May 2, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report first...
April 30, 2012 12:30 ET | Source: Mateon Therapeutics

OXiGENE Reports Data Showing Median Survival and One-Year Survival Improvement in Anaplastic Thyroid Cancer Patients Treated With ZYBRESTAT(R) and Chemotherapy

SOUTH SAN FRANCISCO, Calif., April 30, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer, announced today...
March 13, 2012 16:00 ET | Source: Mateon Therapeutics

OXiGENE Reports Full Year 2011 Financial Results

SOUTH SAN FRANCISCO, Calif., March 13, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGND), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye...
March 06, 2012 08:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Full Year 2011 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., March 6, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
February 06, 2012 08:00 ET | Source: Mateon Therapeutics

OXiGENE to Present at BIO CEO & Investor Conference

SOUTH SAN FRANCISCO, Calif., Feb. 6, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
December 12, 2011 08:00 ET | Source: Mateon Therapeutics

OXiGENE and Azanta A/S Establish Partnership to Provide ZYBRESTAT(TM) for ATC in Europe on Named Patient, Compassionate Use Basis

SOUTH SAN FRANCISCO, Calif., and HELLERUP, Denmark, Dec. 12, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat...